Skip to content

JLS Pharma

Active Private limited companyfounded 2021active for 5 yearsRue des Closières, Meux 21, 5081 La BruyèreKBO/BCE: BE 0771.655.091

Lifetime

4 annual accounts with figures on one time axis
peak of €307,552 in 2022
€295,086▲ 47.2%
peak of €71,664 in 2025
€71,664▲ 913%
peak of €97,762 in 2024
€29,426▼ 69.9%
€203,100▲ 68.8%
peak of 2.8 FTE in 2022
2.6 FTE▼ 7.1%
Board2 names since 2021
2 directors and 1 other
Documentsfilings and deeds
09-07-202622 days before the deadline
2025abbreviated format
Gross margin from €200,413 to €295,086Result from €7,075 to €71,664Dividend €140,000Equity from €97,762 to €29,426Debts from €120,290 to €203,100Investments €5,368

Key points

from the 2025 annual accounts

Equity

€29,426 from €97,762 in 2024

Equity fell by 70% in 1 year.

Result

€71,664 ▲ 913%
€7,0702024€71,7002025

The result rose in 2025 from €7,075 to €71,664.

Turnover

≈ €1.0m estimated

The accounts state no turnover.

Debts

€203,100 87% of the balance sheet
Suppliers 30%Taxes and wages 21%Other 49%

Of this, €173,654 falls due within a year.

Investments

€5,368 5.3 times depreciation
20222025

Green is investment, beige is depreciation.

Position in the sector

€29,426

Less equity than 84% of companies in retail trade. Sector median €314,713 · 13,258 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,715 companies had the same profile as JLS Pharma has now. Each dot stands for 17 companies, two years later.

95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,715 companies, not a prediction for JLS Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 22-01-2021
Director, since 30-09-2025
  • 100 sharesdeed of 27-07-2021
Board & ownership

Recent changes

Registered office moved from Louveigne to Meux The registered office moved from Rue de la China 29, 4141 LOUVEIGNE to Rue des Closières 21 à 5081 Meux · Appointment: (director) · General meeting of 30.09.25 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0771655091
Share cancellation Cancellation of 4 shares · General meeting of 11-10-2022 · Gazette deed
First establishment Büllinger Strasse 8, Butgenbach
All 11 events

Comparable companies

same main activity, similar in size and age
Company
JLS Pharma La Bruyère €232,526 €295,086 12.7% 2.6
PHARMACIE HANKAR Auderghem €205,159 €207,722 -64.7% 3
Pharmacie Clemenceau Anderlecht €278,102 €223,550 37.8% 2.7
AC BIZET Anderlecht €199,908 €199,542 35.9% -
You and Divine Marche-en-Famenne €301,637 €241,633 27.7% -
PHARMACIE VANDECASTEELE Woluwe-Saint-Lambert €388,091 €322,062 48.8% 2.6
PHARMACIE VANDERVELLEN Woluwe-Saint-Lambert €439,239 €305,680 4.8% 2.6

These companies have the same main activity as JLS Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €200,000 and €439,000, founded between 2014 and 2023.

Official details

Source: KBO
Status
Active since 23-07-2021Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 5 others
Establishment unit
2.319.723.8214750 Butgenbach, since 25-07-2021
Financial year end
31 December
Peppol
Reachable since 14-05-2025
Company details

Annual accounts 2025

€232,526▲ 6.6%
Employeeson 31-12-2025
5=
Filing
Filed on 09-07-2026, 22 days before the end of the filing period
Financials

Insights on JLS Pharma

JLS Pharma files the abbreviated format. That format states no turnover. The gross margin fell from €307,552 in 2022 to €295,086 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about JLS Pharma

What is the company number of JLS Pharma?
The company number of JLS Pharma is 0771.655.091. The VAT number is the same number with BE in front: BE 0771.655.091.
Where is JLS Pharma based?
The registered office is at Rue des Closières, Meux 21, 5081 La Bruyère.Company details
What does JLS Pharma do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of JLS Pharma?
JLS Pharma is a private limited company (BV).
When was JLS Pharma founded?
JLS Pharma was founded on 23-07-2021.
Is JLS Pharma still active?
Yes, JLS Pharma is an active enterprise in the KBO register.
How many employees does JLS Pharma have?
JLS Pharma had an average of 2.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of JLS Pharma?
The turnover in financial year 2025 is ≈ €1.0m. This figure is estimated from the gross margin of €295,086 and 42 comparable companies (NACE 477). It probably lies between €800,000 and €1.4m. In financial year 2023 turnover was €1.0m.
Is JLS Pharma profitable?
In financial year 2025, JLS Pharma made a profit of €71,664.
Where can I find the annual accounts of JLS Pharma?
JLS Pharma filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of JLS Pharma due?
JLS Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.